Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 29 out of 100. Getting a diagnosis

Topic: Risk, prevention and care in population studies

Plain-language summary

Dementia, a progressive neurodegenerative disorder affecting memory, cognition, and behaviour, poses a major global health challenge in aging populations. The complexity of early diagnosis and the subtle onset of symptoms often delay intervention. In recent years, artificial intelligence (AI) has emerged as a transformative tool for the early detection, classification, and monitoring of dementia, particularly Alzheimer’s disease. AI-driven models leveraging neuroimaging, clinical data, speech analysis, and digital biomarkers are redefining diagnostic accuracy and efficiency. This review highlights the current advancements, methodologies, and challenges in the application of AI for dementia diagnosis in the elderly, and discusses its implications for clinical practice and future research.

What this study adds

Evidence grade: Low

This review discusses how artificial intelligence using neuroimaging, clinical data, speech analysis, and digital biomarkers may improve early detection and classification of dementia. It is a review of diagnostic approaches and does not report any treatment, cure, or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Joshi, A., Joshi, D. H., & Sandhya, P. (2025). Role of Artificial Intelligence in the Diagnosis of Dementia in the Elderly. International Journal of Community Pharmacy. https://doi.org/10.65301/ijcp.2025.6.3.8

Vancouver

Joshi A, Joshi DH, Sandhya P. Role of Artificial Intelligence in the Diagnosis of Dementia in the Elderly. International Journal of Community Pharmacy. 2025. doi:10.65301/ijcp.2025.6.3.8.

BibTeX

@article{joshi2025-a0dc2da0,
  author  = {Joshi, Anirudh and Joshi, Dr. Hanumanthachar and Sandhya, P.},
  title   = {{Role of Artificial Intelligence in the Diagnosis of Dementia in the Elderly}},
  journal = {International Journal of Community Pharmacy},
  year    = {2025},
  doi     = {10.65301/ijcp.2025.6.3.8},
  url     = {https://doi.org/10.65301/ijcp.2025.6.3.8}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review discusses how artificial intelligence using neuroimaging, clinical data, speech analysis, and digital biomarkers may improve early detection and classification of dementia. It is a review of diagnostic approaches and does not report any treatment, cure, or prevention.

Study details

How this study scored 29/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 28 of the 96 points it could be judged on, which is 29 of 100. Total 29 of 100.28 of the 96 points we could judge = 29 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 28 of the 96 points we could judge it on, which is 29 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (International Journal of Community Pharmacy)
Journal's citation record 0 / 4 International Journal of Community Pharmacy: journal h-index 1 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Sandhya P holds only 3 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Indian Institute of Science Bangalore: institution h-index 466 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 28 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 28 of the 96 points we could judge it on is 29 out of 100.
Total 29 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Getting a diagnosis from nearby years

Also tagged “prevalence”

1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →